Font: Financial Modeling Prep • Oct 29, 2025
In its recent Q3 2025 earnings call, CECO reported an EPS of $0.26, slightly below the Zacks Consensus Estimate of $0.27, resulting in a negative surprise of 3.70%. However, this is a notable improvement from the $0.14 EPS reported in the same quarter last year. Despite the earnings miss, CECO has shown a positive trend, having exceeded EPS expectations in two of the last four quarters.
CECO's revenue for the quarter ending September 2025 was $197.6 million, surpassing the Zacks Consensus Estimate by 4.26%. This marks a significant increase from the $135.51 million reported in the same period last year. CECO has consistently outperformed consensus revenue estimates in the last four quarters, highlighting its strong market position.
The company reported orders totaling $232.9 million, a 44% increase, and a backlog of $719.6 million, up by 64%. CECO's gross profit margin stood at 32.7%, with a gross profit of $64.6 million, up 43%. These figures underscore CECO's robust financial health and growth potential, reinforcing its positive outlook for 2026.
CECO's financial metrics reflect its solid performance. The company has a price-to-earnings (P/E) ratio of 33.06 and a price-to-sales ratio of 2.39. Its debt-to-equity ratio is low at 0.08, indicating conservative debt usage. With a current ratio of 1.33, CECO demonstrates strong liquidity, ensuring it can meet short-term obligations effectively.
|
CTNT§>
Cheetah Net Supply Chain Service Inc.
|
$0.02
-16.07%
|
|
ATER§>
Aterian, Inc.
|
$1.11
69.08%
|
|
SOXS§>
Direxion Daily Semiconductor Bear 3X ETF
|
$15.59
11.12%
|
|
BIYA§>
Baiya International Group Inc. Ordinary Shares
|
$1.53
96.41%
|
|
TZA§>
Direxion Daily Small Cap Bear 3X ETF
|
$5.20
3.53%
|
|
NVDA§>
NVIDIA Corporation
|
$213.17
-1.59%
|
|
CLDI§>
Calidi Biotherapeutics, Inc.
|
$0.22
-5.68%
|
|
CHSN§>
Chanson International Holding
|
$0.04
-30.11%
|
|
INTC§>
Intel Corporation
|
$84.52
-0.55%
|
|
NOK§>
Nokia Oyj
|
$11.30
4.97%
|